search
Back to results

EffectiveNess of a Multimodal preHAbilitation Program in patieNts With Bladder canCEr Undergoing Cystectomy (ENHANCE)

Primary Purpose

Bladder Carcinoma

Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Prehabilitation
Sponsored by
The Netherlands Cancer Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bladder Carcinoma focused on measuring prehabilitation, bladder cancer, exercise, smoking cessation, nutritional support, surgical complications, cystectomy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Histologically confirmed, primary, bladder cancer (cTa-4N0/N+M0),
  • Planned to undergo radical cystectomy,
  • Age ≥ 18 years.

Exclusion Criteria:

  • Subjects with severe cognitive or psychiatric disorders,
  • Subjects who are operated within 3 weeks,
  • Subjects with insufficient command of the Dutch language, which precludes them from following study instructions or completing study questionnaires,
  • Subjects who have contraindications to safely perform exercise training or testing (i.e., CPET),
  • Subject who are unable or unwilling to participate in the intervention.

Sites / Locations

  • Erasmus Medical CenterRecruiting
  • RadboudumcRecruiting
  • UMC GroningenRecruiting
  • UMC UtrechtRecruiting
  • Catharina ZiekenhuisRecruiting
  • Maastricht UMC+Recruiting
  • RijnstateRecruiting
  • Noordwest ZiekenhuisgroepRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Prehabilitation group

Control group

Arm Description

The intervention group will participate in a prehabilitation program of approximately 4-6 weeks before surgery, and additionally during neoadjuvant chemotherapy if applicable. The program consist of a tailored exercise program, nutritional support and if relevant smoking cessation and/or psychological counselling. The exercise program is under supervision of an oncology specialized physiotherapist and comprises aerobic-, resistance- and breathing- and relaxation exercises. A dietician will provide nutritional support and give dietary advice to increase protein intake, including a supplement containing 30 g of whey-protein daily and after supervised training. Patients who score high on anxiety and depression will be offered a referral to a psychologist. Intensive counselling and nicotine replacement therapy will be offered to all patients who smoke. Patients will be asked to keep a diary to track unsupervised activity and to track intake of the protein supplementation.

Patients randomized to the control group will receive care as usual according to local ERAS guideline implementation. In addition, they will receive a leaflet with the recent guidelines regarding physical activity, dietary advice, and smoking cessation. Their actual physical activity level will be obtained via questionnaire.

Outcomes

Primary Outcome Measures

Complications
The proportion of patients having Clavien-Dindo grade 2 or higher perioperative complications; obtained from the medical records

Secondary Outcome Measures

High grade complications
Clavien Dindo grade 3 or higher
Duration of hospital stay
Time from admission until hospital discharge
Readmissions
Hospital readmission as recorded in medical file
Disease status
Progression/recurrence, any additional treatment as recorded in medical file
Change in cardiorespiratory fitness
Assessed via cardiopulmonary exercise test (CPET)
Change in muscle strength
Grip strength
Change in muscle strength
30s chair stands
Change in physical performance
Short Physical Performance Battery (SPPB)
Change in nutritional status
Short Form- Patient Generated Subjective Global Assessment (SF-PGSA)
Change in body composition
Fat free mass and fat mass assessed by Scale Bioelectrical Impedance Analysis (BIA)
Nil per mouth consumption during hospitalization
The total days as recorded in medical file
Change in weight
Measured in KG
Height
Measured in cm
Change in smoking status
Self-developed questionnaire
Sense of coherence (SOC)
13-item SOC questionnaire
Change in fatigue
MFI questionnaire
Change in HRQoL
EORTC QLQ-C30
Change in muscle invasive bladder cancer specific scores
EORTC QLQ-BLM30
Change in health status
EQ-5D-5L
Change in physical activity
SQUASH questionnaire
Change in anxiety and depression
HADS questionnaire
Intervention costs
Cost analysis
Healthcare resources consumption
Medical Consumption Questionnaire (iMCQ)
Work status
Productivity Cost Questionnaire (iPCQ)
Satisfaction with prehabilitation in intervention group and evaluation in control group
Self-developed questionnaire
Non participation analysis
Identify clinical and sociodemographic variables that are related to non-participation of patients in this trial via questionnaire
Hypoxia
To study the effectiveness of the prehabilitation program in terms of inducing favorable changes in tumor hypoxia markers

Full Information

First Posted
July 14, 2022
Last Updated
October 27, 2022
Sponsor
The Netherlands Cancer Institute
Collaborators
UMC Utrecht, University Medical Center Groningen, Radboud University Medical Center, Rijnstate Hospital, Noordwest Ziekenhuisgroep, Erasmus Medical Center, Maastricht University Medical Center, Karolinska Institutet
search

1. Study Identification

Unique Protocol Identification Number
NCT05480735
Brief Title
EffectiveNess of a Multimodal preHAbilitation Program in patieNts With Bladder canCEr Undergoing Cystectomy
Acronym
ENHANCE
Official Title
EffectiveNess of a Multimodal preHAbilitation Program in patieNts With Bladder canCEr Undergoing Cystectomy. The ENHANCE Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 11, 2022 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
October 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Netherlands Cancer Institute
Collaborators
UMC Utrecht, University Medical Center Groningen, Radboud University Medical Center, Rijnstate Hospital, Noordwest Ziekenhuisgroep, Erasmus Medical Center, Maastricht University Medical Center, Karolinska Institutet

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Currently, the potential value of a multimodal prehabilitation program in bladder cancer has not been extensively studied. The investigators designed the ENHANCE study to assess the effect of a structured multimodal prehabilitation program in 154 patients with bladder cancer on the number (primary endpoint) and severity of complications within 90 days, length of hospital stay, readmissions, physical fitness, muscle strength, physical functioning, nutritional status, smoking behaviour, anxiety and depression, fatigue, quality of life, physical activity, tumor tissue characteristics, and healthcare costs.
Detailed Description
The ENHANCE study is a multicenter, randomized controlled trial. The intervention group will participate in a prehabilitation program of 4-6 weeks before surgery, and additionally during neoadjuvant chemotherapy if applicable. The prehabilitation program consist of a tailored exercise program, nutritional support and if relevant smoking cessation and/or psychological counselling. The exercise program is under supervision of an oncology specialized physiotherapist and comprises aerobic-, resistance- and breathing- and relaxation exercises. Patients will be asked to be physically active for an additional 2 times a week for at least 30 minutes. A dietician will provide nutritional support and give dietary advice to increase protein intake to enhance the anabolic effect on muscle mass. Additionally, patients will receive a supplement containing 30 g of high quality whey-protein daily preferably before sleep and after the supervised training. Patients who score high on anxiety and depression will be offered a referral to a psychological support. Intensive counselling and nicotine replacement therapy will be offered to all patients who smoke. Patients in the intervention group will be asked to keep a diary to track unsupervised activity and to track intake of the protein supplementation. The physical activity level in both groups will be obtained via questionnaire.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bladder Carcinoma
Keywords
prehabilitation, bladder cancer, exercise, smoking cessation, nutritional support, surgical complications, cystectomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized Controlled Trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
154 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Prehabilitation group
Arm Type
Experimental
Arm Description
The intervention group will participate in a prehabilitation program of approximately 4-6 weeks before surgery, and additionally during neoadjuvant chemotherapy if applicable. The program consist of a tailored exercise program, nutritional support and if relevant smoking cessation and/or psychological counselling. The exercise program is under supervision of an oncology specialized physiotherapist and comprises aerobic-, resistance- and breathing- and relaxation exercises. A dietician will provide nutritional support and give dietary advice to increase protein intake, including a supplement containing 30 g of whey-protein daily and after supervised training. Patients who score high on anxiety and depression will be offered a referral to a psychologist. Intensive counselling and nicotine replacement therapy will be offered to all patients who smoke. Patients will be asked to keep a diary to track unsupervised activity and to track intake of the protein supplementation.
Arm Title
Control group
Arm Type
No Intervention
Arm Description
Patients randomized to the control group will receive care as usual according to local ERAS guideline implementation. In addition, they will receive a leaflet with the recent guidelines regarding physical activity, dietary advice, and smoking cessation. Their actual physical activity level will be obtained via questionnaire.
Intervention Type
Behavioral
Intervention Name(s)
Prehabilitation
Intervention Description
Multimodal prehabilitation program
Primary Outcome Measure Information:
Title
Complications
Description
The proportion of patients having Clavien-Dindo grade 2 or higher perioperative complications; obtained from the medical records
Time Frame
0-12 weeks post-surgery (measured 4 weeks and 12 weeks post-surgery)
Secondary Outcome Measure Information:
Title
High grade complications
Description
Clavien Dindo grade 3 or higher
Time Frame
0-12 weeks post-surgery
Title
Duration of hospital stay
Description
Time from admission until hospital discharge
Time Frame
0-12 weeks post-surgery
Title
Readmissions
Description
Hospital readmission as recorded in medical file
Time Frame
0-12 weeks post-surgery
Title
Disease status
Description
Progression/recurrence, any additional treatment as recorded in medical file
Time Frame
0-12 weeks post-surgery
Title
Change in cardiorespiratory fitness
Description
Assessed via cardiopulmonary exercise test (CPET)
Time Frame
T0a (baseline), T1 (within 1 week before surgery)
Title
Change in muscle strength
Description
Grip strength
Time Frame
T0a (baseline), T1 (within 1 week before surgery), T3 (12 weeks post-surgery)
Title
Change in muscle strength
Description
30s chair stands
Time Frame
T0a (baseline), T1 (within 1 week before surgery), T3 (12 weeks post-surgery)
Title
Change in physical performance
Description
Short Physical Performance Battery (SPPB)
Time Frame
T0a (baseline), T1 (within 1 week before surgery), T3 (12 weeks post-surgery)
Title
Change in nutritional status
Description
Short Form- Patient Generated Subjective Global Assessment (SF-PGSA)
Time Frame
T0a (baseline), T1 (within 1 week before surgery), T3 (12 weeks post-surgery)
Title
Change in body composition
Description
Fat free mass and fat mass assessed by Scale Bioelectrical Impedance Analysis (BIA)
Time Frame
T0a (baseline), T1 (within 1 week before surgery), T3 (12 weeks post-surgery)
Title
Nil per mouth consumption during hospitalization
Description
The total days as recorded in medical file
Time Frame
0-12 weeks post-surgery
Title
Change in weight
Description
Measured in KG
Time Frame
T0a (baseline), T1 (within 1 week before surgery), T3 (12 weeks post-surgery)
Title
Height
Description
Measured in cm
Time Frame
T0a (baseline) - T3 (12 weeks post-surgery)
Title
Change in smoking status
Description
Self-developed questionnaire
Time Frame
T0a (baseline), T0b (if applicable: after neoadjuvant chemotherapy), T1 (within 1 week before surgery), T2 (4 weeks post-surgery), T3 (12 weeks post-surgery)
Title
Sense of coherence (SOC)
Description
13-item SOC questionnaire
Time Frame
T0a (baseline)
Title
Change in fatigue
Description
MFI questionnaire
Time Frame
T0a (baseline), T0b (if applicable: after neoadjuvant chemotherapy), T1 (within 1 week before surgery), T2 (4 weeks post-surgery), T3 (12 weeks post-surgery)
Title
Change in HRQoL
Description
EORTC QLQ-C30
Time Frame
T0a (baseline), T0b (if applicable: after neoadjuvant chemotherapy), T1 (within 1 week before surgery), T2 (4 weeks post-surgery), T3 (12 weeks post-surgery)
Title
Change in muscle invasive bladder cancer specific scores
Description
EORTC QLQ-BLM30
Time Frame
T0a (baseline), T0b (if applicable: after neoadjuvant chemotherapy), T1 (within 1 week before surgery), T2 (4 weeks post-surgery), T3 (12 weeks post-surgery)
Title
Change in health status
Description
EQ-5D-5L
Time Frame
T0a (baseline), T0b (if applicable: after neoadjuvant chemotherapy), T1 (within 1 week before surgery), T2 (4 weeks post-surgery), T3 (12 weeks post-surgery)
Title
Change in physical activity
Description
SQUASH questionnaire
Time Frame
T0a (baseline), T0b (if applicable: after neoadjuvant chemotherapy), T1 (within 1 week before surgery), T2 (4 weeks post-surgery), T3 (12 weeks post-surgery)
Title
Change in anxiety and depression
Description
HADS questionnaire
Time Frame
T0a (baseline), T0b (if applicable: after neoadjuvant chemotherapy), T1 (within 1 week before surgery), T2 (4 weeks post-surgery), T3 (12 weeks post-surgery)
Title
Intervention costs
Description
Cost analysis
Time Frame
T0a (baseline) - T3 (12 weeks post-surgery)
Title
Healthcare resources consumption
Description
Medical Consumption Questionnaire (iMCQ)
Time Frame
T0a (baseline) - T3 (12 weeks post-surgery) (measured within 1 week before surgery, 4 and 12 weeks post-surgery and if applicable : after neoadjuvant chemotherapy)
Title
Work status
Description
Productivity Cost Questionnaire (iPCQ)
Time Frame
T0a (baseline) - T3 (12 weeks post-surgery)
Title
Satisfaction with prehabilitation in intervention group and evaluation in control group
Description
Self-developed questionnaire
Time Frame
T3 (12 weeks post-surgery)
Title
Non participation analysis
Description
Identify clinical and sociodemographic variables that are related to non-participation of patients in this trial via questionnaire
Time Frame
T0a (baseline)
Title
Hypoxia
Description
To study the effectiveness of the prehabilitation program in terms of inducing favorable changes in tumor hypoxia markers
Time Frame
T3 (12 weeks post-surgery)
Other Pre-specified Outcome Measures:
Title
Overall and bladder-cancer specific survival
Description
Exploratory outcome
Time Frame
0-60 months
Title
Progression-free survival
Description
Exploratory outcome
Time Frame
0-60 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically confirmed, primary, bladder cancer (cTa-4N0/N+M0), Planned to undergo radical cystectomy, Age ≥ 18 years. Exclusion Criteria: Subjects with severe cognitive or psychiatric disorders, Subjects who are operated within 3 weeks, Subjects with insufficient command of the Dutch language, which precludes them from following study instructions or completing study questionnaires, Subjects who have contraindications to safely perform exercise training or testing (i.e., CPET), Subject who are unable or unwilling to participate in the intervention.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Martijn Stuiver, PhD
Phone
+31205124136
Email
m.stuiver@nki.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Emine Akdemir, MSc
Phone
+31683395101
Email
e.akdemir@nki.nl
Facility Information:
Facility Name
Erasmus Medical Center
City
Rotterdam
State/Province
Doctor Molewaterplein 40
ZIP/Postal Code
3015 GD
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joost Boormans
Facility Name
Radboudumc
City
Nijmegen
State/Province
Geert Grooteplein Zuid 10
ZIP/Postal Code
6525 GA
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Toine van der Heijden
Facility Name
UMC Groningen
City
Groningen
State/Province
Hanzeplein 1
ZIP/Postal Code
9713 GZ
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Annemarie Leliveld
Facility Name
UMC Utrecht
City
Utrecht
State/Province
Heidelberglaan 100
ZIP/Postal Code
3584 CX
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne M. May, Prof. dr.
Email
a.m.may@umcutrecht.nl
Facility Name
Catharina Ziekenhuis
City
Eindhoven
State/Province
Michelangelolaan 2
ZIP/Postal Code
5623 EJ
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Evert Koldewijn
Facility Name
Maastricht UMC+
City
Maastricht
State/Province
P. Debyelaan 25
ZIP/Postal Code
6229 HX
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bart Bongers
Facility Name
Rijnstate
City
Arnhem
State/Province
Wagnerlaan 55
ZIP/Postal Code
6815 AD
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carl Wijburg
Facility Name
Noordwest Ziekenhuisgroep
City
Alkmaar
State/Province
Wilhelminalaan 12
ZIP/Postal Code
1815 JD
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Siebe Bos

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
Patients are asked informed consent for data sharing with POLARIS consortium

Learn more about this trial

EffectiveNess of a Multimodal preHAbilitation Program in patieNts With Bladder canCEr Undergoing Cystectomy

We'll reach out to this number within 24 hrs